| Name | HMN-176 |
| Description | HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1). |
| Cell Research | Cells to be tested are seeded into a 96-well microplate at a density of 3 ×103-1×104 cells/well. Drugs are added the next day and the plate is incubated for 72 h at 37 °C in a humidified incubator (5% CO2, 95% air). The inhibition of growth is measuredby the MTT assay, and the concentration required to produce 50% inhibition of growth (IC50) calculated by the Scansoft 96 software program. The IC50 values for HMN-176 andreference agents are presented. Briefly, for each compound the mean IC50 value for all cell lines tested is calculated and the difference between the individual IC50 values and the mean IC50 value (log10) displayed by a bar projecting to the right or left of the mean. The resistance index is calculated as (IC50 value for drug-resistant cell line)/(IC50 for parent cell line). |
| In vitro | HMN-176 at a concentration of 2.5 μM significantly prolongs mitosis in hTERT-RPE1 and CFPAC-1 cell lines, independent of its impact on microtubule polymerization. Concentration-dependently, it inhibits aster formation at doses of 2.5, 0.25, and 0.025 μM. At varying concentrations (0.1, 1.0, or 10.0 µg/mL), HMN-176 exhibits inhibitory effects on breast, non-small-cell lung, and ovarian cancer specimens, with significant activity observed in 63% of breast, 67% of non-small cell lung, and 57% of ovarian tumor specimens treated at 10.0 µg/mL. It shows considerable cytotoxicity across different tumor types from various organs, with a mean IC50 value of 118 nM, indicating a broad cytotoxic effect. Furthermore, a 3 μM treatment of HMN-176 reduces MDR1 mRNA expression by 56%, although it does not significantly affect residual promoter activity. |
| In vivo | HMN-176 prevents spindle assembly and meiosis in Spisula oocytes by inhibiting centrosome-dependent MT nucleation, i.e., aster formation. Oocytes treated with 0.25 μM HMN-176 undergoes GVBD, but asters or spindles fails to form, even after prolonged periods[1]. After p.o. of HMN-214 to male rats, the prodrug is not detected in the plasma, while plasma levels of HMN-176 peaks at 2 h and gradually decreases thereafter[3]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (261.49 mM), Sonication is recommended.
2% DMSO+40% PEG300+5% Tween 80+53% Saline : 2 mg/mL (5.23 mM)
|
| Keywords | Polo-like Kinase (PLK) | plk1 | PLK | Inhibitor | inhibit | HMN-176 | HMN176 | HMN 176 |
| Inhibitors Related | T521 | (E/Z)-Rigosertib sodium | Cyclapolin 9 | SBE13 Hydrochloride | Pyridoxine | Rigosertib sodium | 3MB-PP1 | Ro3280 | Volasertib | Poloxin-2 | BI 2536 | GSK461364 |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Preclinical Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
